Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aytu Biopharma (AYTU) Shares Outstanding (Diluted Average) (2020 - 2025)

Aytu Biopharma (AYTU) has disclosed Shares Outstanding (Diluted Average) for 4 consecutive years, with $5.5 million as the latest value for Q3 2023.

  • On a quarterly basis, Shares Outstanding (Diluted Average) rose 117.72% to $5.5 million in Q3 2023 year-over-year; TTM through Sep 2023 was $5.5 million, a 117.72% increase, with the full-year FY2023 number at $3.3 million, up 127.22% from a year prior.
  • Shares Outstanding (Diluted Average) was $5.5 million for Q3 2023 at Aytu Biopharma, up from $3.3 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $16.7 million in Q2 2021 to a low of $1.3 million in Q3 2021.
  • A 4-year average of $5.5 million and a median of $3.1 million in 2022 define the central range for Shares Outstanding (Diluted Average).
  • Peak YoY movement for Shares Outstanding (Diluted Average): crashed 91.22% in 2022, then soared 173.91% in 2023.
  • Aytu Biopharma's Shares Outstanding (Diluted Average) stood at $13.3 million in 2020, then crashed by 90.06% to $1.3 million in 2021, then skyrocketed by 113.38% to $2.8 million in 2022, then skyrocketed by 94.54% to $5.5 million in 2023.
  • Per Business Quant, the three most recent readings for AYTU's Shares Outstanding (Diluted Average) are $5.5 million (Q3 2023), $3.3 million (Q2 2023), and $3.7 million (Q1 2023).